LRI Investments LLC Increases Stock Holdings in Gilead Sciences, Inc. $GILD

LRI Investments LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,478 shares of the biopharmaceutical company’s stock after buying an additional 138 shares during the quarter. LRI Investments LLC’s holdings in Gilead Sciences were worth $164,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of GILD. Price T Rowe Associates Inc. MD lifted its stake in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares in the last quarter. Nuveen LLC bought a new position in Gilead Sciences during the 1st quarter valued at $620,415,000. Kingstone Capital Partners Texas LLC bought a new position in Gilead Sciences during the 2nd quarter valued at $238,083,000. Los Angeles Capital Management LLC lifted its stake in Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after acquiring an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after acquiring an additional 1,942,433 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares in the company, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares in the company, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 77,000 shares of company stock worth $8,853,430. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $117.18 on Monday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 52-week low of $84.17 and a 52-week high of $121.83. The firm has a market cap of $145.40 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 0.80 and a beta of 0.34. The business’s fifty day moving average is $114.65 and its 200 day moving average is $110.25.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period in the previous year, the company posted $2.01 EPS. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GILD. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 8th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $118.08.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.